← All Coeptis Therapeutics Holdings, INC filings

Coeptis Therapeutics Holdings, INC 8-K filings

NASDAQ
COEP
Coeptis Therapeutics Holdings, INC
8-K: Coeptis Therapeutics Faces Nasdaq Delisting After Failing to Meet Minimum Bid Price Requirement
Coeptis Therapeutics Holdings, Inc. received a delisting notice from Nasdaq after failing to maintain a minimum share price of $1.00, and is planning to appeal the decision.
NASDAQ
COEP
Coeptis Therapeutics Holdings, INC
8-K: Coeptis Therapeutics Secures $4.3 Million in Series A Preferred Offering Led by Board Member
Coeptis Therapeutics has successfully raised $4.3 million through a Series A preferred stock offering, led by a board member, to bolster its cell therapy platform development.
NASDAQ
COEP
Coeptis Therapeutics Holdings, INC
8-K: Coeptis Therapeutics to Restate Past Financials Due to Accounting Errors
Coeptis Therapeutics Holdings, Inc. announced it will restate its financial statements from 2022 and 2023 due to accounting errors related to a merger and a research agreement.
NASDAQ
COEP
Coeptis Therapeutics Holdings, INC
8-K: Coeptis Therapeutics Faces Nasdaq Delisting Risk After Share Price Falls Below $1.00
Coeptis Therapeutics Holdings, Inc. received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, placing its listing status at risk.